SCHEMBL31227342

SCHEMBL31227342

CC(C)(C)OC(=O)N1CCC[C@@H](Nc2nccc3cc(-c4cccnc4)ccc23)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 3/20 0.51
▸ USP30 Q70CQ3 3/20 0.49
▸ GPR119 Q8TDV5 1/20 0.48
▸ PIK3CA P42336 2/20 0.46
▸ KIT P10721 1/20 0.46
▸ PIK3CB P42338 1/20 0.45
▸ PIK3CG P48736 1/20 0.45
▸ KDM1A O60341 1/20 0.44
▸ GBA1 P04062 1/20 0.44
▸ JAK3 P52333 2/20 0.43
▸ PIM1 P11309 2/20 0.43
▸ PIM2 Q9P1W9 2/20 0.43
▸ CYP2C9 P11712 1/20 0.42
▸ IRAK1 P51617 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ CCNK O75909 1/20 0.42
▸ CDK12 Q9NYV4 1/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ ABL1 P00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227195 0.84 PIK3CD (0.48) PIK3CDUSP30PIK3CAPIM1PIM2
SCHEMBL31247168 0.84 PIK3CD (0.48) PIK3CDUSP30PIK3CAPIM1PIM2
SCHEMBL31227119 0.84 ANO1 (0.51) PIK3CDUSP30PIK3CAPIM1PIM2
SCHEMBL16187368 0.83 USP30 (0.50) PIK3CDUSP30JAK3PIM1PIM2
SCHEMBL31227846 0.83 PIK3CD (0.49) PIK3CDUSP30PIK3CAPIM1PIM2
SCHEMBL31227250 0.77 PIM1 (0.47) PIK3CDUSP30JAK3PIM1PIM2
SCHEMBL21598992 0.77 USP30 (0.50) USP30GPR119JAK3PIM1PIM2
SCHEMBL16177034 0.77 USP30 (0.50) USP30JAK3PIM1PIM2JAK2
SCHEMBL16177033 0.77 USP30 (0.50) USP30JAK3PIM1PIM2JAK2
SCHEMBL31227488 0.77 USP30 (0.50) USP30JAK3PIM1PIM2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 PIK3CD 3846/4885USP30 3093/4885GPR119 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback